Neprilysin inhibition for pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled, proof‐of‐concept trial

BACKGROUND AND PURPOSE: Pulmonary arterial hypertension (PAH) is an incurable, incapacitating disorder resulting from increased pulmonary vascular resistance, pulmonary arterial remodelling, and right ventricular failure. In preclinical models, the combination of a PDE5 inhibitor (PDE5i) with a nepr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Pharmacol
Main Authors: Hobbs, Adrian J., Moyes, Amie J., Baliga, Reshma S., Ghedia, Dipa, Ochiel, Rachel, Sylvestre, Yvonne, Doré, Caroline J., Chowdhury, Kashfia, Maclagan, Kate, Quartly, Harriet L., Sofat, Reecha, Smit, Angelique, Schreiber, Benjamin E., Coghlan, Gerry J., MacAllister, Raymond J.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Research Papers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651846/
https://ncbi.nlm.nih.gov/pubmed/30761523
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.14621
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados